Clinical Trials

Multiple clinical trials are evaluating therapeutic interventions across musculoskeletal, urological, neurodegenerative, and dermatological conditions, including thumb carpometacarpal joint arthritis, medial lobe prostatic hyperplasia, mild cognitive decline associated with Alzheimer's disease, and chronic diabetic foot ulcers. Encompassing Phase 1, Phase 2, and phase-not-applicable studies, recruitment statuses range from not yet recruiting to recruiting. Sponsoring organizations include academic institutions and clinical research groups such as the University of Virginia, Seoul National University Hospital, Helse Stavanger HF with the University of Exeter, and NOxy Health Products LLC with SerenaGroup Inc.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06359665 Not yet recruiting
Arthritis of Carpometacarpal Joint of Left Thumb|Arthritis of Carpometacarpal Joint of Right Thumb
Brent DeGeorge|University of Virginia
2024-06-01 Phase 1
NCT06177821 Recruiting
Prostatic Hyperplasia of the Medial Lobe
Seoul National University Hospital
2024-06-03 Not Applicable
NCT06362707 Not yet recruiting
Cognitive Decline Mild|Alzheimer Disease
Helse Stavanger HF|University of Exeter
2024-05-01 Phase 2
NCT06402565 Not yet recruiting
Diabetic Foot Ulcer
NOxy Health Products LLC|SerenaGroup Inc.
2024-05-15 Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Calcium gluconate monohydrate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an essential mineral salt, calcium gluconate dissociates into free calcium ions that interact with voltage-gated ion channels and calmodulin, thereby regulating intracellular signaling cascades, cardiac contractility, and neuromuscular excitability. By restoring systemic calcium balance and preserving cellular membrane potential, this physiological replenishment prevents osteoclastic bone resorption and maintains tissue integrity, supporting clinical applications in musculoskeletal, urological, and neurodegenerative disorders.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.